Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2020-11-30 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
EIB supports AB Science in its COVID-19 development programme
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces a financing deal (€15.0 million loan) between AB Science and the European Investment Bank (EIB) to support clinical development for masitinib related to COVID-19. This content directly relates to fundraising, financing activities, and capital structure changes, specifically debt financing secured from a major institution. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a management discussion (MDA).
2020-11-30 English
La BEI soutient AB Science dans son programme de développement Covid-19
Capital/Financing Update Classification · 1% confidence The document is a press release dated November 30, 2020, announcing a financing agreement between AB Science and the European Investment Bank (BEI) for 15.0 million euros to support the clinical development program for 'masitinib' related to Covid-19 treatment. The text details the loan structure, the inclusion of stock warrants (BSA), and quotes from management and the BEI. This announcement concerns fundraising and capital structure changes, specifically securing a loan (financing activity). This aligns directly with the definition for 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it describes a specific corporate finance event.
2020-11-30 French
AB Science sécurise avec Alpha Blue Ocean un financement optionnel en fonds propres sous la forme d'un PACT dans la limite de 4 millions d'actions
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated November 16, 2020, announcing that AB Science has secured a financing agreement with Alpha Blue Ocean in the form of a PACTTM (Programme d'Augmentation de Capital à Terme). This involves the potential issuance of up to 4 million shares over 24 months to raise capital. The core subject is a fundraising and capital structure activity. This directly aligns with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV). Since it is a detailed announcement about securing financing, it is classified as CAP, not just a general regulatory filing (RNS).
2020-11-16 French
AB Science secures equity financing for a maximum of 4 million shares with Alpha Blue Ocean’s PACT
Capital/Financing Update Classification · 1% confidence The document is a press release dated November 16, 2020, announcing that AB Science has entered into an equity financing facility (PACTTM) with Alpha Blue Ocean to raise capital through the issuance of up to 4 million new shares over 24 months. This transaction directly relates to the company's fundraising and capital structure changes. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA/RNS), as it details the terms and consequences of the financing itself.
2020-11-16 English
AB Science announces a financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares
Capital/Financing Update Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces a specific financial transaction: "FINANCING OF 4.5 MILLION EUROS THROUGH THE ISSUANCE OF CONVERTIBLE BONDS WITH ATTACHED WARRANTS". This involves raising capital through debt instruments (convertible bonds) and warrants, which directly relates to the company's financing activities and capital structure. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER) focusing on operational results, or a general regulatory filing (RNS), as it details the terms of a specific capital raise.
2020-10-29 English
AB Science annonce un financement de 4,5 millions d’euros par émission d’obligations convertibles en actions ordinaires nouvelle
Capital/Financing Update Classification · 1% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a specific financial transaction: a financing of 4.5 million Euros through the issuance of convertible bonds with warrants (OCABSA). This action directly relates to raising capital and changing the company's financing structure. Based on the definitions, this aligns perfectly with the 'Capital/Financing Update' category. Code: CAP (Capital/Financing Update). It is not an Earnings Release (ER) as it focuses on financing, not periodic results. It is not a 10-K or IR as it is a short announcement about a specific event, not a comprehensive report. It is not an RPA because it is the primary announcement of the financing event itself, not just an announcement that a report is forthcoming.
2020-10-29 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.